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In this issue, Kunikowska et al. [1] provide a landmark study
with the first clinical use of a combination of simultaneously
administered (“cocktail”) radio-nuclides. In their theoretical
paradigm [2], each radio-isotope with its spectrum of emitted
beta energies has an optimal target diameter in which most of
the beta energy is absorbed and so-called “energy escape”
prevented, thereby optimising the radiation dose to the
tumour. A cocktail of 50%
90Y -DOTA TA TE (“
90Y”) + 50%
177Lu-DOTA TA TE (“
177Lu”) was used in 25 patients and
compared to another group of 25 patients treated by
90Y-
DOTA TA TE only. This followed pre-clinical work by de Jong
et al., who, using a neuro-endocrine tumour rat model with
one small and one large tumour subcutaneously implanted,
found striking differences in overall survival and progressive
disease in favour of the combination
90Y+
177Lu compared
with each single-agent treatment. Kunikowska et al. found
greater overall survival in patients treated with
90Y+
177Lu
than with
90Yalone and concluded that the tandem therapy is
more effective, although tumour response and progression-
free survival were not significantly different.
A critical issue of this and many other radionuclide therapy
studies isthatpatientswerenotrandomisedtoreceive
90Yalone
or
90Y+
177Lu. In the results section, the authors state that first
one cohort patients were treated with
90Y , then another cohort
with
90Y+
177Lu when
177Lu became available in Poland. It
cannot be stressed enough how important it is to comprehend
the introduction of bias to clinical oncology trials and to
address its potential sources in a systematic way. There are
several tools available, for example the Cochrane risk of bias
toolbox [3]. As clinical trials appear to be biased towards an
exaggeration of treatment differences, guidelines for reporting
of clinical trials have also been adopted by several cancer
journals [4]. These include description of quality control
methods; unaccounted patients; inevaluability rate; exclusion
of ineligibility; power analysis and sample size; initial target
sample size; control patients; patient subsets; and methods of
statistical analysis. According to these guidelines, (definite)
claims of therapeutic efficacy cannot be made on the basis of
non-randomised trials unless the disease is so rare or
prognosis so poor that controlled randomisation is practically
impossible. On the other hand, it has been argued that
randomisation is not necessary because matched historical or
concurrent controls can be selected. However, this is a
misconception, because randomisation does not ensure that
treatment groups are medically equivalent, as done in the
Kunikowska study by statistically comparing a number of
known patient characteristics, but that the unknown biasing
factors are randomly distributed, and thus a statistically
significant difference is not the result of a non-random
difference in these unknown prognostic factors.
Kaplan–Meier survival curves are very suitable to assess
overall survival because they use the actual observed time-
of-death data and interpolate the probability of survival in
between these times. It would have been desirable for all
patients to have attained the same observation period of
36 months, as mentioned in the methods section. In general,
survival models such as Kaplan–Meier analysis classify
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of a clinical trial, as non-informative (i.e. random). Indeed,
the censoring time is independent of the prognosis of the
patient, and hence such events may be considered non-
informative. However, early withdrawal of a patient for
reasons such as lack of compliance, early death and loss to
follow-up can be informative. This can also be the case if
not overall survival but rather other endpoints such as
“event-free survival” are used. Consequently, it is essential
to obtain follow-up information actively on all patients
before analysis. In the study of Kunikowska et al., there is
significantly better overall but not event-free survival,
“event” being defined as progression, relapse or death. In
other words,
90Y+
177Lu patients did not have a better
tumour response, remain tumour-stable for longer or show
slower progression, but they did live longer. This seems
odd, as one would assume tumour-related death to be the
consequence and implication of a preceding tumour
progression. In non-randomised trials, there are three main
sources of bias to consider: differences in prognostic
variables, in co-interventions and/or in outcome measure-
ments. One explanation could thus be a higher number of
disease-unrelated deaths as a result of differences in the
distribution of unknown prognostic variables, resulting in a
higher death rate in the group receiving
90Yonly. Often, the
referral pattern changes with the availability of a new
therapy; over time, more advanced and often also less
advanced cases are included for therapy. Regarding the
presence or lack of co-interventions, such as simultaneously
administered systemic therapy, additional necessary surgery,
or even alternative medicine, this seems not to be an issue,
but is not specifically mentioned. Finally, a drift in
diagnostic tests for measuring outcome can be problematic,
particularly in cohort studies. Tumour progression on the
basis of a subjective assessment of symptoms has to be
evaluated by the same observers that are blinded to the
treatment arm. Systematic discussion of possible sources of
bias and their direction of influence increases the strength
of evidence, especially in non-randomised studies.
While a log-rank test can determine the risk of death
systematically, i.e. if it is higher or lower in one group over a
whole period, another approach, as mentioned in the study by
Kunikowska, has been to apply a proportional hazards or Cox
regression model. To provide a model for the survival of an
individualpatient,thefollowingmodelisused:hi(t)=HRi×h0(t).
This says that the risk of death for a particular patient is
determined by a general “baseline” risk of death h0(t) that can
vary in time and a hazard ratio (HRi) that is constant in time
(the so-called proportional hazard model assumption). This
HR is the ratio of the risk of death in (treatment) group A and
the risk of death in (treatment) group B, for example
177Lu/
90Yv e r s u s
90Y alone. The survival model of Kaplan–
Meier is a robust model that has no additional assumptions,
but in non-randomised studies differences in populations with
regard to prognosis can heavily influence the results. The Cox
regression model allows to determine which factors, or co-
variables, influence survival by making a regression model of
the logarithm of the relative risk: ln (HR)
=β1X1+β2X2+β3X3+...... Why the authors used their partic-
ular co-variables and not others mentioned in the literature,
such as the presence or absence of a carcinoid syndrome,
markers of proliferation, extent of hepatic metastases or
histological features, is unclear. An interesting approach
would have been to see how the hazard ratio of the treatment
group (
90Y+
177Lu versus
90Y) would change with the addition
of other prognostic factors to the model. If such an observed
change in hazard ratio were large, then this would indicate the
possibility that more confounding co-variables were present
and the observed outcome less sure, emphasising the need for
a randomised controlled trial.
Where to go from here? An intriguing question is that the
paradigm of “energy escape” is a seemingly paradox to the
known paradigm of “cross-fire” in which, by virtue of a long
range of the beta particle, several cell diameters including
those cells that have scarcely accumulated the radionuclide
can be effectively treated. If one assumes a homogeneous
mixture and equal affinity of
90Y -DOTA TA TE and
177Lu-
DOTA TA TE, it may be expected that equal amounts of
90Y
and
177Lu are distributed among a wide range of different
sized tumours. While use of
177Lu in small tumours would
provide a clear advantage in humans, the theoretical optimal
diameter of
177Lu and
90Y (2 mm and 34 mm, respectively)
with the size ranges reported in this study (25–75% in the
range 39–91 mm and 30–75 mm, respectively, for
90Yan d
90Y+
177Lu) would imply a theoretical undertreatment of
larger tumours in two ways, i.e. by the limited range of
177Lu
within the tumour and by the lack of cross-fire by
90Y .I na
palliative therapy, in which tumour size is important for
morbidity and quality of life, this may be a different effect
from that in an adjuvant setting, in which small subclinical
tumours may be paramount to tumour recurrence. Since the
authors did not evaluate a group with solely an
177Lu
labelled somatostatin analogue, it remains unclear whether
the seemingly superior outcome of the cocktail group is
driven only by the addition of
177Lu or whether it is really an
effect of the combination. With this latter argument in mind,
it seems reasonable to evaluate this approach in a three-
armed prospective trial. In our opinion, especially in the light
of personalised medicine [5], such a trial should be
performed by employing state-of-the-art dosimetric
approaches. This could potentially lead to the development
of a “personalised cocktail” approach. Abiding by the rules
of experimental oncotherapy under a strict protocol, needed
to increase the level of evidence and the acceptance of
upfront therapy, the study by Kunikowska et al. shows that
this approach could be successful and its paradigm clinically
1786 Eur J Nucl Med Mol Imaging (2011) 38:1785–1787relevant. Thus, this study may well represent the beginning
of an important development in clinical radionuclide therapy.
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